Opexa to Attend the Third International Conference on the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact

THE WOODLANDS, TX--(Marketwired - Apr 27, 2016) -  Opexa Therapeutics, Inc. ( NASDAQ : OPXA ), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, taking place April 28-30, 2016 in Vatican City .

Mr. Warma will join the world's leading cell therapy scientists, physicians, patients, ethicists and leaders of faith, government and philanthropists to discuss the latest cellular therapy breakthroughs and the hope they provide for the future treatment of disease. Mr. Warma's presentation is entitled, "Can T-cells be Used to Treat Neuromyelitis Optica (NMO) and Other Autoimmune Disorders?"

"I am extremely pleased that Opexa is taking part in this global discussion about the importance of immunotherapies and the transformative role they could play in treating life threatening diseases," stated Neil K. Warma, President and Chief Executive Officer of Opexa. "Opexa has been a pioneer in the development of immunotherapies for over a decade. Our lead therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program for the treatment of secondary progressive multiple sclerosis, an area with a serious unmet medical need. It is for patients like these, with limited or no treatment options, that we, as a community, continue to focus on the advancement and development of potentially life changing therapies, and coming together at The Vatican is a step in that direction."

"We're thrilled Neil Warma will be joining us at The Vatican to speak about T-Cells and how they can be used to treat auto-immune disorders," said Dr. Robin Smith, President of The Stem For Life Foundation. "His company, Opexa Therapeutics, has a unique understanding of how cellular therapies can be used to treat a full spectrum of auto-immune disease including neuromyelitis optica (NMO)."

The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact is hosted by The Vatican's Pontifical Council for Culture, the Stem for Life Foundation and STOQ (Science, Theology and the Ontological Quest) Foundation. Moderated by renowned journalists and broadcasted around the world, the 2016 event will have a unique focus on pediatric cancers and rare genetic diseases, as well as diseases that occur with aging. The conference will explore the future and how science, technology, information and communication will allow us to personalize medical solutions to remove inefficiencies, while reducing overall health care costs. The conference will unite people of all races, religious beliefs, cultural and economic backgrounds in a global conversation about the healing potential of cell therapy and the importance of delivering approved therapies to people suffering with debilitating medical conditions around the world.

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the same patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.

For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO .

The Stem For Life Foundation (SFLF) is the educational and advocacy subsidiary of The Cura Foundation and is devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions, as opposed to merely treating their symptoms. The Foundation stands at the forefront of a fundamental shift away from traditional drug treatment in favor of amplifying the body's natural repair mechanisms to vanquish disease. For more information on The Stem For Life Foundation, please visit http://www.stemforlife.org .  To follow the Vatican event on Twitter, please join the conversation @StemForLife or via the hashtag #UNITETOCURE.

Cautionary Statement Relating to Forward-Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna® and OPX-212, constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna and OPX-212, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and OPX-212), as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2015 and our Quarterly Reports on Form 10-Q. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

Company Contact: Camilla Zuckero Opexa Therapeutics, Inc. czuckero@opexatherapeutics.com +1-281-775-0600 Stem For Life Contact: Linda Burns Allison+Partners Phone: +1-646-428-0606 Email: Linda@allisonpr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 125

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 396

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 192

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 92

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 89

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 0

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 272

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 0

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank's Bond Offering Surpasses Expectations with High Demand

Updated Category News Views 193

Inbank's Successful Subordinated Bond Subscription Recently, Inbank wrapped up its public offering of subordinated bonds, marking a significant moment in the company's financial journey. The event attracted considerable attention, with an impressive 935 investors participating, ultimately subscribing to bonds worth a total of 21.6 million euros. This enthusiasm resulted...

Continue Reading
Investors Alert: Class Action Against Starbucks Corporation

Updated Category News Views 87

Class Action Filed Against Starbucks Corporation The Gross Law Firm is reaching out to investors of Starbucks Corporation (NASDAQ: SBUX) following significant financial announcements and issues raised concerning the company's recent performance. The Purpose Behind the Class Action This class action aims to provide shareholders who purchased SBUX stocks during the recently...

Continue Reading
Unlock Your Franchise Potential with Free UT Haslam Courses

Updated Category News Views 185

Revolutionizing Franchising Education The University of Tennessee's Haslam College of Business is proud to offer its franchising certification program without any fees, thanks to the generous support of successful entrepreneur Shelly Sun Berkowitz. As the founder and executive chairwoman of BrightStar Group Holdings Inc., Berkowitz brings invaluable experience to the...

Continue Reading
Ultra Maritime Launches New Facility to Enhance Naval Warfare Solutions

Updated Category News Views 257

Ultra Maritime Opens New Innovative Facility Today marks an exciting new chapter for Ultra Maritime as it inaugurates its latest integrated design and manufacturing center. This state-of-the-art facility is dedicated to supporting the evolving needs of global allied navies, particularly in anti-submarine warfare (ASW). The center, located in Greenford, UK, offers a modern...

Continue Reading
Exciting New Fundraising Initiative by Robin Hood for NYC

Updated Category News Views 395

Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...

Continue Reading